At the rapid oral session here at ASCO 2025, we reported updates from the NATALEE trial. We looked at menopausal status and we also looked at age and gave updates. Previously, we’d seen data with a median follow-up of around 33 months. Now we presented data with a median follow-up of 44 months. What we saw is that in patients in NATALEE against stage 2-3, hormone receptor positive or triple negative disease, we ended up seeing that patients continue to have this persistent benefit even after stopping ribociclib...
At the rapid oral session here at ASCO 2025, we reported updates from the NATALEE trial. We looked at menopausal status and we also looked at age and gave updates. Previously, we’d seen data with a median follow-up of around 33 months. Now we presented data with a median follow-up of 44 months. What we saw is that in patients in NATALEE against stage 2-3, hormone receptor positive or triple negative disease, we ended up seeing that patients continue to have this persistent benefit even after stopping ribociclib. And that absolute benefit with ribociclib only continues to increase, and it was increased in premenopausal patients as well as postmenopausal patients. And then we looked by subgroups, in particular patients, for instance, who were less than 40 years of age because we know that these patients can be at a higher risk for recurrence. We saw, regardless of age, that there was a benefit that was seen with the addition of ribociclib. We also looked at quality of life outcomes with the QLQ-C30, and we saw that there was no additional quality of life impact by taking ribociclib. So ultimately, the data demonstrated that across different endpoints, whether it’s invasive disease-free survival, distant relapse-free survival, et cetera, that ribociclib is helping regardless of age in subgroup.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
